Insider · CIK 0001016835

RIGGS RORY B

Reports to the SEC for 5 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001016835

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-02	CBUSCibus, Inc. · Stock Option (Right-to-Buy)A Award	Director	AAward	+77.6K sh	—	—	77,586
2026-01-29	CBUSCibus, Inc.A Award	Director	AAward	+333K sh	$1.50	+$500K	14,916,640
2025-06-09	CBUSCibus, Inc.X Exercise of In-Money	Director	XExercise of In-Money	+4M sh	$0.00	+$400	14,533,307
2025-06-09	CBUSCibus, Inc.X Exercise of In-Money	Director	XExercise of In-Money	+50K sh	$0.01	+$500	14,583,307
2025-06-09	CBUSCibus, Inc. · Pre-Funded Warrant (right to buy)X Exercise of In-Money	Director	XExercise of In-Money	−4M sh	—	—	0
2025-06-09	CBUSCibus, Inc. · Pre-Funded Warrant (right to buy)X Exercise of In-Money	Director	XExercise of In-Money	−50K sh	—	—	0
2025-06-05	CBUSCibus, Inc.A Award	Director	AAward	+5.71M sh	$1.75	+$10M	10,533,307
2025-05-22	CBUSCibus, Inc. · Stock Option (Right-to-Buy)A Award	Director	AAward	+39.3K sh	—	—	39,301
2025-04-02	Intra-Cellular Therapies, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−132K sh	$132.00	−$17.4M	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.8K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,009 sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,322 sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−2,951 sh	—	—	0
2025-01-21	CBUSCibus, Inc. · Common WarrantA Award	Director	AAward	+4M sh	—	—	4,000,000
2025-01-21	CBUSCibus, Inc. · Pre-Funded WarrantA Award	Director	AAward	+4M sh	$2.50	+$10M	4,000,000
2024-12-31	Intra-Cellular Therapies, Inc.A Award	Director	AAward	+215 sh	$83.52	+$18K	131,512
2024-12-31	CBUSCibus, Inc.C Conversion	Director	CConversion	−1.39M sh	—	—	0
2024-12-31	CBUSCibus, Inc.C Conversion	Director	CConversion	+1.39M sh	—	—	4,839,912
2024-12-31	CBUSCibus, Inc. · Cibus Common UnitC Conversion	Director	CConversion	−1.39M sh	—	—	0
2024-09-30	Intra-Cellular Therapies, Inc.A Award	Director	AAward	+246 sh	$73.17	+$18K	117,108
2024-09-18	CBUSCibus, Inc.A Award	Director	AAward	+250K sh	$4.00	+$1M	3,451,828
2024-06-28	Intra-Cellular Therapies, Inc.A Award	Director	AAward	+262 sh	$68.49	+$17.9K	116,862
2024-06-24	Intra-Cellular Therapies, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+20K sh	$16.86	+$337K	121,062
2024-06-24	Intra-Cellular Therapies, Inc.S Sale	Director	SSale	−4,462 sh	$75.57	−$337K	116,600
2024-06-24	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−20K sh	—	—	0
2024-06-23	Intra-Cellular Therapies, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,567 sh	—	—	101,062
2024-06-23	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,567 sh	—	—	0
2024-06-14	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	Director	AAward	+2,951 sh	—	—	2,951
2024-06-14	Intra-Cellular Therapies, Inc.Stock Option (right to buy)A Award	Director	AAward	+4,322 sh	—	—	4,322
2024-06-11	CBUSCibus, Inc.A Award	Director	AAward	+98K sh	$10.20	+$1M	3,201,828
2024-06-11	CBUSCibus, Inc. · Common WarrantA Award	Director	AAward	+98K sh	—	—	98,040
2024-03-31	Intra-Cellular Therapies, Inc.A Award	Director	AAward	+260 sh	$69.20	+$18K	99,495
2024-03-20	Intra-Cellular Therapies, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+20K sh	$18.56	+$371K	99,235
2024-03-20	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−20K sh	—	—	0
2024-02-20	RPRXRoyalty Pharma plcC Conversion	Director	CConversion	+300K sh	—	—	320,099
2024-02-20	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	Director	CConversion	−30K sh	—	—	270,000
2024-01-04	RPRXRoyalty Pharma plcS Sale	Director	SSale	−35.7K sh	$27.55	−$984K	20,099
2024-01-03	RPRXRoyalty Pharma plcS Sale	Director	SSale	−199K sh	$27.79	−$5.53M	55,801
2024-01-02	RPRXRoyalty Pharma plcS Sale	Director	SSale	−235K sh	$28.52	−$6.71M	254,899
2023-12-31	Intra-Cellular Therapies, Inc.A Award	Director	AAward	+251 sh	$71.62	+$18K	79,235
2023-12-29	CBUSCibus, Inc.J Other	Director	JOther	+1.51M sh	—	—	2,867,193
2023-12-29	CBUSCibus, Inc.C Conversion	Director	CConversion	−1.5M sh	—	—	1,367,193
2023-12-29	CBUSCibus, Inc.C Conversion	Director	CConversion	+1.5M sh	—	—	3,103,788
2023-12-29	CBUSCibus, Inc. · Cibus Common UnitsJ Other	Director	JOther	+1.51M sh	—	—	2,867,193
2023-12-29	CBUSCibus, Inc. · Cibus Common UnitsC Conversion	Director	CConversion	−1.5M sh	—	—	1,367,193
2023-12-12	CBUSCibus, Inc.P Purchase	Director	PPurchase	+517K sh	$10.58	+$5.47M	1,622,495

Recent filings

Accepted (ET)
Jun 44
RIGGS RORY B0001615594-26-000042
SEC(opens sec.gov)
Feb 24
RIGGS RORY B0001193125-26-034092
SEC(opens sec.gov)
Jun 114
RIGGS RORY B0000950170-25-084928
SEC(opens sec.gov)
Jun 104
RIGGS RORY B0000950170-25-084320
SEC(opens sec.gov)
May 274
RIGGS RORY B0001615594-25-000073
SEC(opens sec.gov)
Apr 24
RIGGS RORY B0000950170-25-049648
SEC(opens sec.gov)
Jan 234
RIGGS RORY B0000950170-25-008350
SEC(opens sec.gov)
Jan 104
RIGGS RORY B0001615594-25-000004
SEC(opens sec.gov)

Companies

Address

6455 NANCY RIDGE DRIVE

SAN DIEGO, CA, 92121